THERANEXUS EO -25
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
THERANEXUS EO -25 (3VG) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, THERANEXUS EO -25 (3VG) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
THERANEXUS EO -25 - Net Assets Trend (None–None)
This chart illustrates how THERANEXUS EO -25's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for THERANEXUS EO -25 (None–None)
The table below shows the annual net assets of THERANEXUS EO -25 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to THERANEXUS EO -25's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
THERANEXUS EO -25 Competitors by Market Cap
The table below lists competitors of THERANEXUS EO -25 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harbour Link Group Bhd
KLSE:2062
|
$27.95 Million |
|
Falcon Power Co Ltd
TW:1516
|
$27.95 Million |
|
Canadian North Resources Inc.
OTCGREY:CNRSF
|
$27.95 Million |
|
CombinedX AB
ST:CX
|
$27.96 Million |
|
Tidewater Renewables Ltd
PINK:TDWRF
|
$27.93 Million |
|
EOFLOW Co.Ltd
KQ:294090
|
$27.93 Million |
|
Roto Pumps Limited
NSE:ROTO
|
$27.93 Million |
|
Swiss Properties Invest A/S
CO:SWISS
|
$27.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in THERANEXUS EO -25's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares THERANEXUS EO -25's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently THERANEXUS EO -25 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares THERANEXUS EO -25's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| THERANEXUS EO -25 (3VG) | €- | N/A | N/A | $27.95 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |